What Has Been The Evolution of the PEGylated Proteins Market in Recent Years?
The pegylated proteins market has seen considerable growth due to a variety of factors.
• The pegylated proteins market has grown rapidly in recent years. It will increase from $1.47 billion in 2024 to $1.68 billion in 2025, at a compound annual growth rate (CAGR) of 14.1%.
The growth is driven by improved therapeutic efficacy, an aging population, the demand for long-acting formulations, better drug safety profiles, and expanding applications in targeted drug delivery systems.
What Are the Future Growth Projections for the PEGylated Proteins Market?
The pegylated proteins market is expected to maintain its strong growth trajectory in upcoming years.
• The pegylated proteins market is expected to grow rapidly, reaching $2.8 billion by 2029, with a CAGR of 13.7%.
Growth drivers include investments in rare diseases, biopharmaceutical industry growth, precision medicine, biosimilar competition, and innovative market access strategies. Major trends include digital health integration, next-gen pegylation technologies, personalized formulations, combination therapies, and patient-centric healthcare.
What Are The Core Factors Supporting Growth In The PEGylated Proteins Market?
The surging incidence rate of lifestyle-related diseases is projected to fuel the expansion of the PEGylated proteins market. These diseases stem mainly from unhealthy behaviors and lifestyle choices like poor diet, lack of exercise, and smoking. The escalation in lifestyle diseases can be attributed to a mix of factors such as reduced physical activity, deteriorating diets rich in processed foods, and heightened stress levels. PEGylated proteins are deployed in the treatment of lifestyle diseases by improving the effectiveness, duration, and targeted transportation of therapeutic agents for issues like cardiovascular diseases, diabetes, and specific cancers. As an example, the Office for Health Improvement and Disparities, a government agency based in the UK, reported in May 2024 that for the 2022 to 2023 period, an estimated 64.0% of English adults aged 18 and above were identified as overweight or obese, marking a minimal rise from 63.8% in 2021 to 2022. Consequently, the rising incidence rate of lifestyle-related diseases is spurring the growth of the PEGylated proteins market.
What Are The Major Segments Within The Global PEGylated Proteins Market?
The pegylated proteins market covered in this report is segmented –
1) By Product: Consumable And Services, PEGylation Kits And Reagents, Monofunctional Linear PEGs, Bifunctional PEGs, Services, Other Products
2) By Protein Type: Colony Stimulating Factors, Interferons, Erythropoietin, Recombinant Factor VII, Other Protein Types
3) By Application: Cancer Treatment, Hepatitis, Chronic Kidney Diseases, Hemophilia, Multiple Sclerosis, Gastrointestinal Disorders, Other Applications
4) By End User: Pharmaceuticals, Biotechnology Companies, Contract Research Organizations, Academic Research Institutes
Subsegments:
1) By Consumable And Services: Consumables, Services (Contract Services, PEGylation Services)
2) By PEGylation Kits And Reagents: PEGylation Kits, Reagents
3) By Monofunctional Linear PEGs: Monofunctional PEGs For Protein Modification
4) By Bifunctional PEGs: Bifunctional PEGs For Protein Modification
5) By Other Products: Conjugates, PEGylated Drugs And Therapeutics
Pre-Book The PEGylated Proteins Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The PEGylated Proteins Market?
Key players in the PEGylated protein industry are striving to outpace their competitors by creating original products like PEGylation reagents. These substances are chemical compounds that bind polyethylene glycol (PEG) chains to biomolecules, subsequently influencing their properties for a range of biomedical uses. In a depiction of this, Creative Enzymes, a US company specialising in food additives and enzymes, rolled out DSPE-PEG-Maleimide in May 2023, specifically designed for drug delivery purposes. DSPE-PEG-Maleimide (DSPE-PEG-MAL) is a unique PEGylation reagent with DSPE phospholipids and maleimide at its core. It's a versatile self-assembly compound used in the creation of PEGylated liposomes or micelles and offers thiol or cysteine reactive maleimide groups. This product is frequently used for targeted drug deliveries.
Who Are the Key Players In The PEGylated Proteins Market?
Major companies operating in the PEGylated proteins market are:
• Merck & Co. Inc.
• Bayer AG
• Bristol Myers Squibb Company
• AstraZeneca PLC
• Roche Holding AG
• Gilead Sciences Inc.
• Novo Nordisk A/S
• Evonik Industries AG
• Viatris Inc.
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Vertex Pharmaceuticals Incorporated
• Lonza Group Ltd.
• Jazz Pharmaceuticals plc
• Ipsen Pharma
• Kyowa Kirin Co. Ltd.
• WuXi Biologics
• BioMarin Pharmaceutical Inc.
• Ligand Pharmaceuticals Incorporated
• Zydus Cadila
• Enzon Pharmaceuticals Inc.
What Is The Most Dominant Region In The PEGylated Proteins Market?
North America was the largest region in the PEGylated Proteins market in 2024. The regions covered in the PEGylated proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
